| Autor: |
Rogers RS; Just Biotherapeutics, Seattle, Washington, USA. rich@just.bio., Abernathy M; Amgen, Thousand Oaks, California, USA., Richardson DD; Merck, Kenilworth, New Jersey, USA., Rouse JC; Pfizer, Andover, Massachusetts, USA., Sperry JB; Pfizer, St. Louis, Missouri, USA., Swann P; Biogen, Cambridge, Massachusetts, USA., Wypych J; Amgen, Thousand Oaks, California, USA., Yu C; Genentech, South San Francisco, California, USA., Zang L; Biogen, Cambridge, Massachusetts, USA., Deshpande R; Amgen, Thousand Oaks, California, USA. |
| Abstrakt: |
Today, we are experiencing unprecedented growth and innovation within the pharmaceutical industry. Established protein therapeutic modalities, such as recombinant human proteins, monoclonal antibodies (mAbs), and fusion proteins, are being used to treat previously unmet medical needs. Novel therapies such as bispecific T cell engagers (BiTEs), chimeric antigen T cell receptors (CARTs), siRNA, and gene therapies are paving the path towards increasingly personalized medicine. This advancement of new indications and therapeutic modalities is paralleled by development of new analytical technologies and methods that provide enhanced information content in a more efficient manner. Recently, a liquid chromatography-mass spectrometry (LC-MS) multi-attribute method (MAM) has been developed and designed for improved simultaneous detection, identification, quantitation, and quality control (monitoring) of molecular attributes (Rogers et al. MAbs 7(5):881-90, 2015). Based on peptide mapping principles, this powerful tool represents a true advancement in testing methodology that can be utilized not only during product characterization, formulation development, stability testing, and development of the manufacturing process, but also as a platform quality control method in dispositioning clinical materials for both innovative biotherapeutics and biosimilars. |
Full text from SpringerLink